stoxline Quote Chart Rank Option Currency Glossary
  
(CELG)
  0 (0%)    03-28 15:18
Open:
High:
Volume: 0
  
Pre. Close:
Low:
Market Cap: 0(M)
Technical analysis
2024-03-28 2:48:44 PM
Short term     
Mid term     
Targets 6-month :  232.23 1-year :  271.24
Resists First :  198.83 Second :  232.23
Pivot price 174.41
Supports First :  157.12 Second :  131.35
MAs MA(5) :  184.06 MA(20) :  174.92
MA(100) :  133.16 MA(250) :  110.9
MACD MACD :  9.9 Signal :  10
%K %D K(14,3) :  61.5 D(3) :  69.5
RSI RSI(14): 72.3
52-week High :  198.83 Low :  74.16
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CEG ] has closed below upper band by 16.7%. Bollinger Bands are 45.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 190.2 - 191.48 191.48 - 192.54
Low: 179.93 - 181.16 181.16 - 182.17
Close: 183.08 - 185.09 185.09 - 186.74
Company Description

Headline News

Fri, 12 Jan 2024
Chutes & Ladders—Former Celgene CEO Alles takes the top job at TORL - Fierce Biotech

Tue, 19 Dec 2023
Celgene discovers new PADI4 inhibitors - BioWorld Online

Fri, 08 Sep 2023
Natco Pharma, Celgene Corp, others sued in US for generic cancer drug - Business Standard

Thu, 03 Aug 2023
Bristol Myers, BeiGene end legacy Celgene deal with settlement years after China ban - FiercePharma

Thu, 13 Jul 2023
Flagship recruits former BMS, Celgene R&D chief Rupert Vessey - STAT

Fri, 21 Apr 2023
Celgene, BMS, Teva Can't Pause Cancer Drugs Antitrust Suit - Law360

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
Sector:
Industry:
Shares Out 315 (M)
Shares Float 316 (M)
Held by Insiders 0.2 (%)
Held by Institutions 87.6 (%)
Shares Short 5,550 (K)
Shares Short P.Month 4,800 (K)
Stock Financials
EPS 5.01
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 34.45
Profit Margin 6.5 %
Operating Margin -2.5 %
Return on Assets (ttm) 2 %
Return on Equity (ttm) 13.9 %
Qtrly Rev. Growth -21 %
Gross Profit (p.s.) 0
Sales Per Share 79.08
EBITDA (p.s.) 13.13
Qtrly Earnings Growth 0 %
Operating Cash Flow -5,300 (M)
Levered Free Cash Flow -1,610 (M)
Stock Valuations
PE Ratio 36.82
PEG Ratio 0.9
Price to Book value 5.35
Price to Sales 2.33
Price to Cash Flow -10.98
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android